1 / 1

Etrasimod(Velsipity)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Pfizer Inc.

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Velsipity(Etrasimod) Instructions:Uses,Dosage, Side Effects

VELSIPITY contains the active ingredient etrasimod, which functions as a sphingosine 1-phosphate (S1P) receptor modulator. It is supplied as 2 mg film-coated tablets for oral administration once daily. The medication works by modulating the immune system, specifically by reducing the migration of lymphocytes from lymphoid tissues into the bloodstream and inflamed intestinal areas, thereby helping to control the inflammation associated with ulcerative colitis.

Generic name

Etrasimod(Velsipity)

English name

Etrasimod

Alternative Names

Velsipity

Drug prices

Indications

To reduce the risk of myocardial infarction and coronary revascularization in adults with established cardiovascular disease (CVD) or at high risk for a CVD event who are unable to take recommended statin therapy.

As an adjunct to diet, alone or combined with other LDL-C-lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

Therapeutic Target

Adenosine triphosphate-citrate lyase (ACL)

Active Ingredients

Bempedoic acid

Dosage form

TABLET

specifications

2mg * 28 tablets/box

Description

Dosage and Administration

Recommended dose: 180 mg orally once daily.

May be taken with or without food.